We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




HIV Testing Critical to Reducing New Infections

By LabMedica International staff writers
Posted on 14 Jul 2011
A three-year initiative to test 2.8 million Americans for Human immunodeficiency virus (HIV) expanded access to testing in 25 United States areas most affected by the virus. More...


The program cost US$111 million and resulted in the diagnosis of 18,432 people who were unaware of their HIV status.

The effort, which was sponsored by the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA), ran from October 2007 through September 2010 and helped state and local health departments support routine HIV testing in a variety of health care locations. A main focus was blacks, who are among the US populations most severely affected by HIV.

Although thirty years have passed since the CDC first reported AIDS-like disease, continuing to raise awareness about HIV and encouraging people to be tested remain important public health goals. Illinois Department of Public Health director Dr. Damon T. Arnold said, "On the 30th anniversary of the awareness of the disease, it remains critically important for people to get tested, know their HIV status, and be knowledgeable about their lives and health."

CDC currently funds 30 areas to reach populations at a higher risk for HIV, including African-Americans, gay, and bisexual men, Latinos, and injection drug users. The CDC launched its expanded testing to support 2006 recommendations for HIV testing to become a routine part of health care for adolescents and adults.

The three-year initiative's focus on testing African-Americans was successful, the centers reported. Hospital emergency rooms, STD clinics, and community-based organizations were three important types of venues in which testing occurred. Chicago was one of the 25 jurisdictions featured in the initiative.

Dr. Kevin Fenton, director of CDC's National Center for HIV/AIDS, Viral Hepatitis, sexually transmitted diseases (STD) and tuberculosis (TB) prevention, was quoted as saying in a recent CDC news release. "These results demonstrate that the nation is making steady progress toward that vision. But more than half of US adults aged 18 to 64 still have never been tested for HIV, and our work is far from over."

Related Links:
US Centers for Disease Control and Prevention




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.